Telix Pharmaceuticals Ltd ADR (TLX) reached a 52-week high of $12.48, pushing its market capitalization to $4.09 billion, following a strong set of first-half results and continued momentum in its oncology pipeline.
The company reported first-half 2026 revenue of AUD 477 million, a 22% increase from the prior-year period. Net profit after tax came in at AUD 38 million, while EBITDA jumped 146% to AUD 52 million. Telix maintained its full-year revenue guidance.
Shares have climbed 22% over the past year and surged roughly 60% in the last six months. The stock trades near its 52-week high, and analysis from InvestingPro suggests it may be slightly overvalued relative to its fair value estimate.
On the pipeline front, Telix completed patient enrollment for the Phase 3 BiPASS trial, which evaluates the effectiveness of Illuccix and Gozellix plus MRI in detecting prostate cancer. The milestone coincides with ongoing regulatory pathway discussions with the U.S. Food and Drug Administration.
H.C. Wainwright reiterated a Buy rating on the stock, maintaining a price target of $20.00, well above the current trading level.
